A 55-year-old man with GPA (granulomatosis with polyangiitis) previously in remission on rituximab maintenance develops rising ANCA titer (PR3-ANCA ×4 rise), but no clinical symptoms or organ damage. What is the recommended management per EULAR vasculitis guidelines?
- A Increase rituximab dosing immediately
- B No change — treat the patient not the titer
- C Repeat ANCA at 3 months; treat clinically if rise persists without symptoms ✓
- D Switch to cyclophosphamide-based re-induction
Explanation
Per EULAR 2022 recommendations for ANCA-associated vasculitis, asymptomatic ANCA titer rises without clinical relapse should not automatically trigger re-induction therapy. However, a significant sustained rise (typically ≥4-fold) warrants heightened clinical vigilance and more frequent monitoring, as ~50% of such patients relapse within 6–12 months. The 'treat the titer' approach is not guideline-endorsed; re-induction is reserved for clinical relapse evidence. This avoids over-immunosuppression. Repeat measurement at 3 months with close clinical monitoring is appropriate.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.